Compare Stocks: ANL, AKBA, SIGA, and AEON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.26 -0.8%	$0.26	$0.18 ▼ $1.45	$13.05M	0.65	2.33 million shs	310,652 shs
AKBA Akebia Therapeutics	$0.89 -0.3%	$1.01	$0.81 ▼ $3.20	$248.34M	0.19	7.16 million shs	3.40 million shs
ANL Adlai Nortye	$15.40 -0.8%	$14.12	$0.88 ▼ $17.25	$1.00B	1.04	161,676 shs	63,505 shs
SIGA Siga Technologies	$3.46 +0.3%	$3.14	$2.83 ▼ $9.29	$247.88M	0.97	684,412 shs	640,552 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	0.00%	+8.70%	-16.10%	-64.36%	-68.69%
AKBA Akebia Therapeutics	0.00%	-2.13%	+2.00%	-19.26%	-67.29%
ANL Adlai Nortye	0.00%	-1.33%	+12.37%	+36.11%	+797.69%
SIGA Siga Technologies	0.00%	+9.87%	+12.75%	-4.43%	-62.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.26 -0.8%	$0.26	$0.18 ▼ $1.45	$13.05M	0.65	2.33 million shs	310,652 shs
AKBA Akebia Therapeutics	$0.89 -0.3%	$1.01	$0.81 ▼ $3.20	$248.34M	0.19	7.16 million shs	3.40 million shs
ANL Adlai Nortye	$15.40 -0.8%	$14.12	$0.88 ▼ $17.25	$1.00B	1.04	161,676 shs	63,505 shs
SIGA Siga Technologies	$3.46 +0.3%	$3.14	$2.83 ▼ $9.29	$247.88M	0.97	684,412 shs	640,552 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	0.00%	+8.70%	-16.10%	-64.36%	-68.69%
AKBA Akebia Therapeutics	0.00%	-2.13%	+2.00%	-19.26%	-67.29%
ANL Adlai Nortye	0.00%	-1.33%	+12.37%	+36.11%	+797.69%
SIGA Siga Technologies	0.00%	+9.87%	+12.75%	-4.43%	-62.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	2.80	Moderate Buy	$1.33	409.68% Upside
AKBA Akebia Therapeutics	2.43	Hold	$3.90	336.68% Upside
ANL Adlai Nortye	2.71	Moderate Buy	$29.50	91.56% Upside
SIGA Siga Technologies	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ANL, AKBA, SIGA, and AEON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/15/2026	AKBA Akebia Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
9/10/2026	ANL Adlai Nortye	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$31.00
9/9/2026	AEON AEON Biopharma	Laidlaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$1.80
9/8/2026	ANL Adlai Nortye	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
9/8/2026	AKBA Akebia Therapeutics	Westpark Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.50
9/8/2026	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/31/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	AEON AEON Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00 ➝ $1.20
8/11/2026	SIGA Siga Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
AKBA Akebia Therapeutics	$236.20M	1.05	N/A	N/A	$0.12 per share	7.44
ANL Adlai Nortye	$5M	198.35	N/A	N/A	($0.21) per share	-73.33
SIGA Siga Technologies	$94.57M	2.63	$0.33 per share	10.36	$2.78 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$4.42	1.45	N/A	N/A	N/A	N/A	-994.63%	11/13/2026 (Estimated)
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	11/9/2026 (Estimated)
ANL Adlai Nortye	-$35.53M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	$23.28M	-$0.05	N/A	N/A	N/A	-5.19%	-1.55%	-1.32%	11/5/2026 (Estimated)

Latest ANL, AKBA, SIGA, and AEON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	SIGA Siga Technologies	N/A	$0.17	N/A	$0.17	N/A	$41.00 million
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
AKBA Akebia Therapeutics	0.99	1.43	1.35
ANL Adlai Nortye	0.04	9.55	0.65
SIGA Siga Technologies	N/A	21.72	16.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
AKBA Akebia Therapeutics	33.92%
ANL Adlai Nortye	35.21%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	9.40%
AKBA Akebia Therapeutics	4.30%
ANL Adlai Nortye	N/A
SIGA Siga Technologies	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	8	49.88 million	74.37 million	Not Optionable
AKBA Akebia Therapeutics	194	277.11 million	265.19 million	Optionable
ANL Adlai Nortye	109	64.40 million	N/A	Not Optionable
SIGA Siga Technologies	49	71.85 million	69.89 million	Optionable

ANL, AKBA, SIGA, and AEON Headlines

Recent News About These Companies

SIGA Technologies stock holds value as small cap metrics guide investors

September 22, 2026 | ad-hoc-news.deA

SIGA Technologies stock gains on solid Q2 earnings and cash position

September 20, 2026 | ad-hoc-news.deA

NASDAQ Composite Index-Wert SIGA Technologies-Aktie: So viel hätten Anleger mit einem Investment in SIGA Technologies von vor einem Jahr verloren

September 8, 2026 | finanzen.netF

SIGA Tech (SIGA): Profits Drop 65%, But Cash and Special Payouts Remain

September 6, 2026 | insidermonkey.com

BlackRock Inc. Makes New $15.24 Million Investment in Siga Technologies Inc. $SIGA

September 4, 2026 | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Shares Up 2.6% - Should You Buy?

August 31, 2026 | marketbeat.com

NASDAQ Composite Index-Wert SIGA Technologies-Aktie: So viel hätten Anleger mit einem Investment in SIGA Technologies von vor 10 Jahren verdient

August 31, 2026 | finanzen.netF

SIGA Technologies, Inc. (SIGA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

SIGA Technologies 2026年第二季度每股收益$0.17，盘后股价小幅上涨

August 6, 2026 | cn.investing.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2026

August 6, 2026 | markets.businessinsider.com

SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results

July 30, 2026 | globenewswire.com

Siga Technologies: Q2 Earnings Due, New TPOXX Orders A Must

July 28, 2026 | seekingalpha.com

Is SIGA Technologies’ (SIGA) Index Shift and ESOP Shelf Registration Reframing Its Defensive Identity?

June 30, 2026 | finance.yahoo.com

Discovering SIGA Technologies And 2 Other Compelling Penny Stocks

May 22, 2026 | finance.yahoo.com

SIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's Changed

May 15, 2026 | finance.yahoo.com

Some Investors May Be Willing To Look Past SIGA Technologies' (NASDAQ:SIGA) Soft Earnings

May 14, 2026 | finance.yahoo.com

SIGA (SIGA) Q1 2026 Earnings Call Transcript

May 8, 2026 | fool.com

SIGA expects Q2 delivery of approximately $13M of oral TPOXX while targeting an FDA PEP submission in the next 12 months

May 8, 2026 | msn.com

SIGA Technologies, Inc. Q1 2026 Earnings Call Summary

May 8, 2026 | finance.yahoo.com

SIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call Transcript

May 8, 2026 | seekingalpha.com

SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update

May 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANL, AKBA, SIGA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.26 0.00 (-0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$0.26 +0.00 (+0.15%)

As of 07:48 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Akebia Therapeutics NASDAQ:AKBA

$0.89 0.00 (-0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$0.89 +0.00 (+0.10%)

As of 07:45 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Adlai Nortye NASDAQ:ANL

$15.40 -0.13 (-0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$15.27 -0.13 (-0.84%)

As of 07:30 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Siga Technologies NASDAQ:SIGA

$3.46 +0.01 (+0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$3.44 -0.02 (-0.43%)

As of 07:30 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, AKBA, SIGA, and AEON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, AKBA, SIGA, and AEON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, AKBA, SIGA, and AEON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, AKBA, SIGA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

Akebia Therapeutics NASDAQ:AKBA

Adlai Nortye NASDAQ:ANL

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANL, AKBA, SIGA, and AEON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANL, AKBA, SIGA, and AEON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANL, AKBA, SIGA, and AEON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANL, AKBA, SIGA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

Akebia Therapeutics NASDAQ:AKBA

Adlai Nortye NASDAQ:ANL

Siga Technologies NASDAQ:SIGA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools